Order Article Reprints

Yun NK, Rouhani SJ, Bestvina CM, Ritz EM, Gilmore BA, Tarhoni I, Borgia JA, Batus M, Bonomi PD, Fidler MJ. Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy. Cancers. 2021; 13(6):1426. https://doi.org/10.3390/cancers13061426

Yun, Nicole K., Sherin J. Rouhani, Christine M. Bestvina, Ethan M. Ritz, Brendan A. Gilmore, Imad Tarhoni, Jeffrey A. Borgia, Marta Batus, Philip D. Bonomi, and Mary Jo Fidler. 2021. "Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy" Cancers 13, no. 6: 1426. https://doi.org/10.3390/cancers13061426

Yun, N. K., Rouhani, S. J., Bestvina, C. M., Ritz, E. M., Gilmore, B. A., Tarhoni, I., Borgia, J. A., Batus, M., Bonomi, P. D., & Fidler, M. J. (2021). Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy. Cancers, 13(6), 1426. https://doi.org/10.3390/cancers13061426